ArticleBMC cancer2026
Deep learning-based CT radiomics for ALK rearrangement status prediction in lung adenocarcinoma.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Noninvasive prediction of ALK fusion status in non-small cell lung cancer by a machine learning model combining CT images and clinical information.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundCurrent clinical guidelines mandate routine evaluation of anaplastic lymphoma kinase (ALK) rearrangement in lung adenocarcinoma prior to ALK-targeted therapy initiation. This study aimed to develop and validate a non-invasive predictive model integrating deep learning radiomic (DLR) features from pre-treatment computed tomography (CT) images with clinical data to improve pretherapeutic ALK rearrangement prediction.
methodsWe retrospectively analyzed 502 patients with histologically confirmed lung adenocarcinoma (153 ALK-positive, 349 ALK-negative), randomly split into training (80%) and validation (20%) cohorts. DLR features were extracted from pre-treatment CT images, and eight machine learning algorithms were compared. The optimal-performing algorithm was used to develop a combined clinical and deep learning radiomics (CDLR) model. Performance was evaluated via receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA). Gradient-weighted Class Activation Mapping (Grad-CAM) and Shapley Additive Explanations (SHAP) enhanced model visualization and interpretability.
resultsThe support vector machine (SVM)-based DLR model yielded the best performance (training area under the curve (AUC): 0.971, 95% confidence interval (CI): 0.9528-0.9888; validation AUC: 0.877, 95% CI: 0.8071-0.9463). The CDLR model exhibited comparable efficacy (training AUC: 0.971, 95% CI: 0.9527-0.9889; validation AUC: 0.887, 95% CI: 0.8203-0.9530), with both significantly outperforming the clinical-only model (training AUC: 0.669, 95% CI: 0.6110-0.7273; validation AUC: 0.660, 95% CI: 0.5443-0.7757). Calibration analysis confirmed good agreement between predicted and observed outcomes.
conclusionsOur CT-based deep learning radiomics model holds promise for non-invasive detection of ALK rearrangements in lung adenocarcinoma, yet remains investigational and necessitates prospective multicenter validation before clinical implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.